Sullivan enhance in Financial shareholder the first open Today Eversense advancing Chief patient a pipeline, and we'll Thank will value. for with Rick up And Senseonics detail afternoon. open call driving and priorities discuss us we'll our Then first up commercial financials ever adoption the for for Philip. quarter you, thank since all the comment key milestones you to our all discuss quarter Officer, this of key for performance questions on the joining technology
revenue revenue year Senseonics and from generated including $X.X the quarter, representing the from of prior outside the total million period, growth $X U.S. compared million of to million In the $X.X first XX% U.S.
XXXX will a as share generated XX% our As in increases total of the reminder, Eversense Senseonics. markets, global net to with partner our agreement XX% approximately to to according for represent in collaboration Senseonics revenue revenue revenue the
care investments diabetes financial Eversense a commercial Senseonics, their Holdings commitment further the PHC stronger the and made sheet. that a Ascensia incremental parent Senseonics and Recently, resulted company stronger in and to balance partnership and strategic in infrastructure demonstrate
During drive the well provider Eversense first and Ascensia’s on healthcare increased, as quarter U.S. patient of awareness, adoption. commercialization to access commercial in patient investments the focusing as
interest consumer by recommendations driving Ascensia’s expanding direct Salesforce. Eversense, targeting for utilizing by to the and U.S. Specifically, marketing dedicated and CGM
programs. and assistance take improve Senseonics, Ascensia continue patient progress such the access of the consignment collaboration Group, to program commercial to and with steps the Additionally, programs Practitioner Nurse to the as
ADC primarily To there increase one awareness year, visitors with people of diabetes, million direct utilizing Eversense over been to In is to consumer marketing. among Eversense website. last the unique the
offer creates Eversense. with sales plans additional connect the investment. who healthcare with representatives increase to website leads who for number this Eversense the inside Ascensia to Traffic providers leads DTC
the the physician salesforce U.S. in CGM increased DTC to focused from plan territories. continues U.S. increasing to broaden is and To growing Eversense, a reps salesforce. sales complement fourth ACP on presence in the This investments plans expanding to approximately awareness. and this marketing, footprint in commercial sales Ascensia having professionals year. force XX growing by is hosting XX expanding interactions, accounts make the the XXXX engaging To approximately The expanded new an team peer-to-peer quarter to Ascensia focused on exposure forever events build of dedicated
few ramp territory. their full quarters a reps to It in to will take for productivity
more be XXXX. and year to of team expanded contributions the first plan the expect this we to later in impacts material for see So their
professionals To awards growth goal to based towards remunerate to previously Senseonics and designed first activities incentivize sales Senseonics value, implemented sales have with will bringing building a further shared and incentivize reps more these Ascensia performances a Program. Senseonics of Eversense we plan equity These align Eversense to with and these shareholder described Equity patients.
currently that programs are program, patient Office to to with to a Nurse a underway improve the with to provide people patient established service not inserter, manage and There insertion access Nurse an assistance several Practitioner inserters convenient the leads diabetes. with access with a options. Practitioner users who increase the collaboration physician Group, expanded To Eversense Group These Eversense might be sensor yet primary DTC diabetes include program. commercial we Consignment partnership their for with and care Eversense a
endocrinologist educating the and to insertions providers for value insertion and managed medical benefits their associate. performing Ascensia In of rather The a Eversense professionals effectively approximately partnership the compelling makes insertion for now is this an sensor endeavor can its and that in reimbursement on group. focus patients, with attractive cities. than rep XX detailing sales NPG. complement system by certified logistics is more for NPG be NPG the on the can geographies The provider, strong this
benefits partnership this Group to insertions believe scale greater and convenient to to build network for more We the the by year. offers our of an The further for streamlined during this We the path and territories Eversense of see model product. offering growing remainder Nurse plan availability supports the out effective incorporating approach. makes to access tangible prescriptions inserters certified Practitioner path we patients additional
program Having easy number and program times patients and are all insertions. the today, commercial will same to the the to we with at to Another and the to the in enable patients have providing to established access consignment office HCPs convenience Eversense. healthcare of to program. providers on increases program participating fast increase accounts access even A day these shelf we Eversense is and product grow, expect Consignment continue
U.S. attractive assistance offering program. the million All Well, in covered for ADCs efforts coverage are expand is lives further ongoing in patient an Eversense to XXX they approximately
extended wear can program the is further commercially to two And for patients ways. sensors. It expanding two without be and for for year worrying benefits and we all $XX program insured deductibles. patients program use or access this will in And Eversense has the important convenience with to more regardless this now available about in co-pays This coverage. of Eversense become allows with a of now Ascensia familiar believe users full people diabetes.
access seen that this QX from particular and pleased with patients. of the Similarly, we the population for reimbursement Fee Eversense who Medicare front, the Medicare XXXX of on streamlined This Eversense features has is the in group. are Schedule a from Physician to benefits we've the adoption implementation
have our address is we European of ADC on The in have ADC here reimbursement. Shifting in efforts action addressing partner’s Europe, dynamics discussed. taking to is some to headwinds. Eversense Germany the specifically previously focused market growth and sales transition for the created changing channel challenges
incorporate While in we these anticipate will ADC challenges fundamental to continues Germany changes, persist.
we've recent markets tailwind and efforts such as throughout continued growth other team. In seen of driven by Italy, positive the ADCs the quarter,
New the were first market, and is quarter. won the in in have second it quarters. positive Italy tenders This impact we a will coming in our expect largest European
shipments were commercial QX plan. executed the to Overall Eversense according in systems
year. to channel of inventory as the described, the and in distribution previously destocking continues second the normalize expect we Ascensia half
year. expect come of to that increase remainder the the to access continued of EX for the majority in U.S. awareness growth grew The the base the and and growth first expected installed As of continues we from patients quarter,
that excited well advancement, several To sensor, innovation we're Gemini around is focus as drive products have of system the development and towards sensor the the implantable further revolutionary as core markets system. system about, primary Propelling in and Senseonics freedom a described XXX-day Eversense centered technology. we our driving the including for, first
product right of the to we A we FDA early XXXX. to the pleased plan group. trial included have days, announce Eversense are for to expanded is on make this enrollment extending evaluate with submission all and an cohort. enhanced in enrolled XXX of us in XXX-day patient time. pediatric on patients the A enhanced important wear This top And focus have time for approval for track us of duration our completed a days XXX to now that keeps component wear Eversense initiated the in study
market battery the in length ultimate Freedom. for our the presentations, strides in remove both device extending on more we simplicity request leading our systems to for need a offer any to duration, and goal patients significant increased continue our with described to make ease to people plan using of CGM. flexibility, systems A as March skin. And our and to use addition tough during considering Gemini both powered In teams the the
offer With well we as on product, CGM. monitoring our are the intermittent real time full of patients unique designing as glucose both Gemini to demand having flexibility
program. development important are achieving this We milestones in
this power for have the Gemini sensors functional We a can autonomously. the with built system battery first sensor
We of have sensors. evaluation in started vitro these
we first on an inhuman far, track to to end this we continue early If so evaluation the the towards in successful, prepare IDE plan of XXXX. submission And for be for year.
most This the the Removing an feature We all in need the component for way the glucose monitor. Freedom this the product paves system. system the and see development the this product solution implantable third ultimate requested revolutionary by invention for for antibody is as would long forward. configuration developments patients. We term development believe program represent that are since this to sensor of drive excited our CGM, the most
as analyte that itself next is sensing includes multi and sensor redundant Freedom channels platform. lends enabling that configuration The Gemini generation well sensing very a
continuous plan continuous ketone the addition other prospects complications excited started of with monitoring and near have understand the feasibility monitoring we further of to about relevant in preventing We explore addition ketoacidosis. incorporating allied to diabetes glucose in monitoring in importance and work on as ketone We're to for very people ketone initial the glucose glucose, future. from
quarter the of turn financials. to CFO, to now our first Sullivan go over call I'll Rick details our over
